Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii

BACKGROUND: Tigecycline, with broad in vitro antibacterial activity, has been widely used off-label for nosocomial pneumonia caused by multi-drug resistant Acinetobacter baumannii (MDRAB). However, many concerns have been raised about the efficacy of tigecycline treatment as the inconsistent results...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:BMC Pharmacol Toxicol
Main Authors: Zhou, Yangang, Chen, Xumin, Xu, Ping, Zhu, Yan, Wang, Kuangguo, Xiang, Daxiong, Wang, Feng, Banh, Hoan Linh
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2019
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6482491/
https://ncbi.nlm.nih.gov/pubmed/31023357
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40360-019-0300-3
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים